Characteristics | No. (%), Mean or Median (IQR) | |
---|---|---|
N = 259,873 (899,392.8 person-years) | Percentage (95% CI) | |
Age in years (Mean ± SD) | 56.6 ± 14.0 |  |
 Median (Q1, Q3) | 56.1 (47.2, 65.8) |  |
Age groups (years) | ||
 20–49 | 84,032 | 32.3 (32.2–32.5) |
 50–64 | 106,526 | 41.0 (40.8–41.2) |
 65–74 | 42,107 | 16.2 (16.1–16.4) |
 75–99 | 27,208 | 10.5 (10.4–10.6) |
Sex | ||
 Female | 122,233 | 47.0 (46.8–47.2) |
 Male | 137,640 | 53.0 (52.8–53.2) |
Region of residence | ||
 Rural | 42,669 | 16.4 (16.3–16.6) |
 Urban | 217,204 | 83.6 (83.4–83.7) |
Number of Charlson Comorbidities | ||
 0 | 175,227 | 67.4 (67.3–67.6) |
 1–2 | 69,443 | 26.7 (26.6–26.9) |
  ≥ 3 | 15,203 | 5.9 (5.8–5.9) |
Charlson comorbidities | ||
 Peripheral vascular disease | 4721 | 1.8 (1.8–1.9) |
 Dementia | 5008 | 1.9 (1.9–2.0) |
 Chronic pulmonary disease | 38,808 | 14.9 (14.8–15.1) |
 Rheumatologic disease | 4849 | 1.9 (1.8–1.9) |
 Peptic ulcer disease | 4406 | 1.7 (1.7–1.8) |
 Mild liver disease | 5010 | 1.9 (1.9–2.0) |
 Diabetes without chronic complications | 20,065 | 7.7 (7.6–7.8) |
 Diabetes with chronic complications | 5247 | 2.0 (2.0–2.1) |
 Hemiplegia or paraplegia | 525 | 0.2 (0.2–0.2) |
 Renal disease | 5344 | 2.1 (2.0–2.1) |
 Any malignancy, including leukemia and lymphoma | 17,208 | 6.6 (6.5–6.7) |
 Moderate or severe liver disease | 583 | 0.2 (0.2–0.2) |
 Metastatic solid tumor | 2294 | 0.9 (0.9–0.9) |
Lab test results | ||
 LDL-cholesterol (> 3.5 mmol/L) | 87,633 | 33.7 (33.5–33.9) |
 Blood glucose (≥7.0 mmol/L) | 53,337 | 20.5 (20.4–20.7) |
 eGFR (< 60 mL/min/1.73m2) | 63,697 | 24.5 (24.4–24.7) |
 HbA1c (≥6.5%) | 36,016 | 13.9 (13.7–14.0) |
 At least one lab test | 157,934 | 60.8 (60.6–61.0) |
Medications | ||
 Thiazide diuretics | 64,248 | 24.7 (24.6–24.9) |
 Beta blockers | 47,089 | 18.1 (18.0–18.3) |
 Calcium channel antagonists | 62,112 | 23.9 (23.7–24.1) |
 Agents acting on the renin-angiotensin system | 174,891 | 67.3 (67.1–67.5) |
 Miscellaneous antihypertensives | 5245 | 2.0 (2.0–2.1) |
  ≥ 1 of the medications listed above | 209,729 | 80.7 (80.6–80.9) |
 Follow-up years (median (Q1, Q3)) | 3.6 (2.2, 4.8) |  |